ERBB2 and breast cancer: It has been demonstrated that the beneficial anticancer effect of rapamycin is mainly based on the arresting cells in G1 phase due to destabilization and subsequent down-regulation of cyclin D3 protein in HER2-overexpressing breast cancer cells [26].